Abstract:The prevalence rate of diabetes is the highest in chronic metabolic diseases of China, the incidence rate of malignant tumors is also increasing year by year, and they are closely related. Systematic and standardized guidance is deficient in the management of tumor associated hyperglycemia. Endocrinology and oncology experts from the Onco-endocrinology Society of Chinese Anti-Cancer Association and Onco-endocrinology Society of Chongqing Integrative Medicine Association have summarized the research progress and evidence-based basis of tumor associated hyperglycemia, and drafted the Guidelines for the Management of Tumor Associated Hyperglycemia (2021 Edition), which provides a systematic and detailed introduction to the conception, clinical diagnosis, treatment and follow-up of tumor associated hyperglycemia. In order to comprehend relevant opinions better, we provide an interpretation in this paper.
